The Challenge of Anticoagulation: Getting Research Into Practice

The Challenges of Cancer-associated Thrombosis

Activity Details
  • Credit Amounts:
    • CME: 0.50
    • Other: 0.50
  • Cost: Free
  • Release: May 3, 2017
  • Expires: May 2, 2020
  • Estimated Time to Complete:
    30 Minutes
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Faculty

Gerald A.  Soff Gerald A. Soff, MD
Chief, Hematology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Needs Statement

Important new evidence has recently emerged on the treatment of cancer-associated thrombosis. Patients with cancer carry an increased risk of developing VTE because of tumor- and treatment-mediated hypercoagulability. Clinical risk factors for VTE in cancer include the primary site of cancer, use of systemic therapy (chemotherapy, erythropoiesis-stimulating agents, exogenous estrogens, and antiangiogenesis therapies), recent surgery, limited mobility, advanced age and comorbidities, and hospitalization. The focus is on this special group of patients with VTE outlining new evidence on NOACs in this setting and discussing the latest AT10 guidelines from American College of Chest Physicians.  

Target Audience

Health care professionals who are faced with challenges of anticoagulation treatment including the management of patients with VTE and/or patients with atrial fibrillation. These include practicing cardiologists, hematologists/oncologists, and geriatricians as well as specialists in Emergency Medicine, Internal Medicine, and all other subspecialist clinicians interested in anticoagulant therapy.

Objectives

Upon completion of this educational activity, participants will be able to:

  • Discuss the clinical relevance of cancer in the development of thrombosis
  • Improve the selection of anticoagulant for the management of cancer-associated thrombosis
  • Identify the relative contraindications to anticoagulant therapy in cancer patients
  • Implement the recommended management plan for a patient with suspected or confirmed chemotherapy-induced thrombocytopenia

Accreditation

CME
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, and Thrombosis Research Institute. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Other
UK Healthcare CECentral certifies this activity for 0.50 hours of participation.

Faculty Disclosure

Christopher B. Granger, MD, (Planner) has relevant financial relationships with commercial interests as follows:
Armetheon - Principal Investigator, Research Support, Salary Support
AstraZeneca - Principal Investigator, Consultant & Other Services, Research Support, Consulting Fee
Bayer - Principal Investigator, Consultant & Other Services, Salary Support, Consulting Fee
Boehringer Ingelheim - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Bristol Myers Squibb - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Eli Lilly - Consultant & Other Services, Consulting Fee
Daiichi Sankyo - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
FDA - Principal Investigator, Research Support
Gilead - Consultant & Other Services, Consulting Fee
Glaxo SmithKline - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Hoffman-La Roche - Consultant & Other Services, Consulting Fee
Janssen Pharmaceuticals - Principal Investigator, Research Support
The Medicines Company - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Medtronic Foundation - Principal Investigator, Research Support, Salary Support

Lord Ajay Kakkar, BSc, MBBS, PhD, FRCS, (Planner) has relevant financial relationships with commercial interests as follows:
Aspen Pharma - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria
Bayer Healthcare - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria
Boehringer Ingelheim Pharma - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria
Daiichi Sankyo Europe - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria
Sanofi SA - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria

Gerald A. Soff, MD, (Speaker) has relevant financial relationships with commercial interests as follows:
Janssen Pharmaceuticals - Principal Investigator, Board or Committee Member, Research Support, Honoraria

No other planners or reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky and Thrombosis Research Institute.

Supported by an unrestricted educational grant from Bayer.

FRONTLINE 2 Survey

The Fundamental Research in Oncology and Thrombosis (FRONTLINE 2) Survey is designed to evaluate how clinicians perceive the risk of venous thromboembolism in cancer patients and to provide insight into current strategies for thromboprophylaxis and management. It has been developed with the guidance of an international advisory board of experts in this field. This survey is coordinated by the Thrombosis Research Institute, London. It has been developed with the guidance of an international advisory board of experts in this field. All replies will be treated in the strictest confidence. The survey is split into 5 Sections (A-E) and will take approximately 20 - 30 minutes to complete.

To complete the survey, visit http://frontline2.tri-london.ac.uk/

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.